Empowered Funds
ACRV icon

Empowered Funds’s Acrivon Therapeutics ACRV Stock Holding History

Empowered Funds’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$117K Buy
+57,036
New +$108K ﹤0.01% 2393

Other funds holding ACRV

Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Empowered Funds's ACRV Position: Q3 2026 in Review

Empowered Funds opened a new position in Acrivon Therapeutics (ACRV) in Q3 2026: 57,036 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #2393 among its holdings.

33 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Empowered Funds held 57,036 shares of Acrivon Therapeutics worth $117K as of Q3 2026.
  • Acrivon Therapeutics was a new Empowered Funds position in Q3 2026.
  • Acrivon Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2393 holding.
  • 33 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.